Epigenetic Regulation in Cardiovascular Diseases: Mechanisms and Therapeutic Targets

Abstract

Cardiovascular diseases (CVDs) arise as the product of multiple factors, including genetic predisposition and environmental exposure, but the molecular and cellular interplays underlying such a pathogenetic process leading to sustained pathological conditions remain largely unknown. A growing body of evidence indicates that epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodeling, noncoding RNAs, and RNA modifications, are important for cardiovascular development, adaptation, and disease. However, findings from these studies are fragmented across different genomic contexts or disease-focused scenarios, lacking systematic integration for a global view connecting epigenetic dynamics to cardiovascular phenotypes and their clinical implications. An overall picture of epigenetic modulation in CVDs is therefore provided. Common epigenetic mechanisms are described in a cell type and disease stage-specific context, and the roles of environmental and lifestyle factors in remodeling the cardiovascular epigenome are illustrated. Novel epigenetic biomarkers and therapeutic interventions are also assessed. Emphasis is placed on epigenomic plasticity, enhancer focused control, and network-level reprogramming as key concepts that drive disease remodeling. By unifying mechanistic understanding with translational evidence, this review frames CVD as a disorder of stabilized regulatory states and defines avenues for precision epigenomic manipulation.

Keywords

cardiovascular diseases / chromatin remodeling / enhancer rewiring / epigenetic regulation / noncoding RNAs / precision epigenetic therapy

References

[1] A. Naeem, S. H. Abbas, M. Yousaf, et al., “Global Impact and Strategies to Reduce the Mortality From Cardiovascular Diseases,” Integrated Science for Sustainable Development Goal 3 25 (2024): 283–306.

[2] D. Wong, G. Auguste, C. L. Lino Cardenas, et al., “FHL5 Controls Vascular Disease-Associated Gene Programs in Smooth Muscle Cells,” Circulation Research 132 (2023): 1144–1161.

[3] M. von Scheidt, Y. Zhao, and T. Q. de Aguiar Vallim, “Transcription Factor MAFF (MAF Basic Leucine Zipper Transcription Factor F) Regulates an Atherosclerosis Relevant Network Connecting Inflammation and Cholesterol Metabolism,” Circulation 143 (2021): 1809–1823.

[4] F. M. Farina, S. Serio, I. F. Hall, et al., “The Epigenetic Enzyme DOT1L Orchestrates Vascular Smooth Muscle Cell-Monocyte Crosstalk and Protects Against Atherosclerosis via the NF-κB Pathway,” European Heart Journal 43 (2022): 4562–4576.

[5] R. Chakraborty, A. C. Ostriker, Y. Xie, et al., “Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity,” Circulation 145 (2022): 1720–1737.

[6] J. Gao, M. Liu, M. Lu, et al., “Integrative Analysis of Transcriptome, DNA Methylome, and Chromatin Accessibility Reveals Candidate Therapeutic Targets in Hypertrophic Cardiomyopathy,” Protein & Cell 15 (2024): 796–817.

[7] T. Zhao, H. J. Kee, L. Bai, et al., “Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway,” Frontiers in Pharmacology 12 (2021): 677757.

[8] L. Wang, S. Wang, T. Jia, et al., “Dexmedetomidine Prevents Cardiomyocytes From Hypoxia/Reoxygenation Injury via Modulating Tetmethylcytosine Dioxygenase 1-Mediated DNA Demethylation of Sirtuin1,” Bioengineered 13 (2022): 9369–9386.

[9] M. Saheli, V. Pirhajati Mahabadi, and S. A. Mesbah-Namin, “DNA Methyltransferase Inhibitor 5-Azacytidine in High Dose Promotes Ultrastructural Maturation of Cardiomyocyte,” Stem Cell Investigation 7 (2020): 22.

[10] M. Chaffin, I. Papangeli, B. Simonson, et al., “Single-Nucleus Profiling of Human Dilated and Hypertrophic Cardiomyopathy,” Nature 608 (2022): 174–180.

[11] P. Kiessling and C. Kuppe, “Spatial Multi-Omics: Novel Tools to Study the Complexity of Cardiovascular Diseases,” Genome Medicine 16 (2024): 14.

[12] E. Schoger, K. J. Carroll, L. M. Iyer, et al., “CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart,” Circulation Research 126 (2020): 6–24.

[13] X. Zhang, J. Sun, A. Canfrán-Duque, et al., “Deficiency of Histone Lysine Methyltransferase SETDB2 in Hematopoietic Cells Promotes Vascular Inflammation and Accelerates Atherosclerosis,” JCI Insight 6 (2021): e147984.

[14] N. Zhong, X. Nong, J. Diao, et al., “piRNA-6426 Increases DNMT3B-Mediated SOAT1 Methylation and Improves Heart Failure,” Aging (Albany NY) 14 (2022): 2678–2694.

[15] L. Kerrigan, K. Edgar, A. Russell-Hallinan, et al., “Integrin Beta-Like 1 Is Regulated by DNA Methylation and Increased in Heart Failure Patients,” ESC Heart Failure 12 (2025): 150–165.

[16] H. Zhu, X. Wang, X. Meng, et al., “Selenium Supplementation Improved Cardiac Functions by Suppressing DNMT2-Mediated GPX1 Promoter DNA Methylation in AGE-Induced Heart Failure,” Oxidative Medicine and Cellular Longevity 2022 (2022): 5402997.

[17] L. Zhao, T. You, Y. Lu, et al., “Elevated EZH2 in Ischemic Heart Disease Epigenetically Mediates Suppression of NaV1.5 Expression,” Journal of Molecular and Cellular Cardiology 153 (2021): 95–103.

[18] Y. Yang, Q. Li, X. Liu, et al., “The Combination of Decitabine With Multi-Omics Confirms the Regulatory Pattern of the Correlation Between DNA Methylation of the CACNA1C Gene and Atrial Fibrillation,” Frontiers in Pharmacology 15 (2024): 1497977.

[19] S. Kashyap, M. Rabbani, I. de Lima, et al., “HOPX Plays a Critical Role in Antiretroviral Drugs Induced Epigenetic Modification and Cardiac Hypertrophy,” Cells 10 (2021): 3458.

[20] H. Zhou, H. J. Kee, L. Wan, et al., “YAK577 Attenuates Cardiac Remodeling and Fibrosis in Isoproterenol-Infused Heart Failure Mice by Downregulating MMP12,” Korean Circulation Journal 55 (2025): 231–247.

[21] C. Lan, C. Chen, S. Qu, et al., “Inhibition of DYRK1A, via Histone Modification, Promotes Cardiomyocyte Cell Cycle Activation and Cardiac Repair After Myocardial Infarction,” EBioMedicine 82 (2022): 104139.

[22] M. Zhang, C. Wang, R. Wang, et al., “Adenosine Kinase Promotes Post-Infarction Cardiac Repair by Epigenetically Maintaining Reparative Macrophage Phenotype,” Journal of Molecular and Cellular Cardiology 174 (2023): 88–100.

[23] W. Liu, X. Cai, S. Duan, et al., “E3 Ubiquitin Ligase Smurf1 Promotes Cardiomyocyte Pyroptosis by Mediating Ubiquitin-Dependent Degradation of TRIB2 in a Rat Model of Heart Failure,” International Review of Immunology 44 (2025): 165–179.

[24] J. Liu, W. Li, K.-Q. Deng, et al., “The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy,” Circulation Research 130 (2022): 1586–1600.

[25] K. Hou, J. Shen, J. Yan, et al., “Loss of TRIM21 Alleviates Cardiotoxicity by Suppressing Ferroptosis Induced by the Chemotherapeutic Agent Doxorubicin,” EBioMedicine 69 (2021): 103456.

[26] Y. Asare, T. A. Campbell-James, Y. Bokov, et al., “Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability,” Circulation Research 127 (2020): 811–823.

[27] S. Wu, J. Zhang, C. Peng, et al., “SIRT6 Mediated Histone H3K9ac Deacetylation Involves Myocardial Remodelling Through Regulating Myocardial Energy Metabolism in TAC Mice,” Journal of Cellular and Molecular Medicine 27 (2023): 3451–3464.

[28] S. Ranjbarvaziri, A. Zeng, I. Wu, et al., “Targeting HDAC6 to Treat Heart Failure With Preserved Ejection Fraction in Mice,” Nature Communications 15 (2024): 1352.

[29] N. Zhang, Y. Zhang, H. Qian, et al., “Selective Targeting of Ubiquitination and Degradation of PARP1 by E3 Ubiquitin Ligase WWP2 Regulates Isoproterenol-Induced Cardiac Remodeling,” Cell Death & Differentiation 27 (2020): 2605–2619.

[30] D. Zhao, G. Zhong, J. Li, et al., “Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination,” Circulation 144 (2021): 694–711.

[31] Y. Kawase, Y. Sunagawa, K. Shimizu, et al., “6-Shogaol, an Active Component of Ginger, Inhibits p300 Histone Acetyltransferase Activity and Attenuates the Development of Pressure-Overload-Induced Heart Failure,” Nutrients 15 (2023): 2232.

[32] Y. Jia, Q. Wang, M. Liang, et al., “KPNA2 Promotes Angiogenesis by Regulating STAT3 Phosphorylation,” Journal of Translational Medicine 20 (2022): 627.

[33] R. S. Haworth, K. Stathopoulou, A. J. Candasamy, et al., “Neurohormonal Regulation of Cardiac Histone Deacetylase 5 Nuclear Localization by Phosphorylation-Dependent and Phosphorylation-Independent Mechanisms,” Circulation Research 110 (2012): 1585–1595.

[34] W. Wei and A. V. Smrcka, “Internalized β2-Adrenergic Receptors Inhibit Subcellular Phospholipase C-Dependent Cardiac Hypertrophic Signaling,” BioRxiv (2023), 2023.06.07.544153.

[35] Y. Chen, Z. Liu, Z. Hu, et al., “Tripartite Motif 27 Promotes Cardiac Hypertrophy via PTEN/Akt/mTOR Signal Pathways,” Bioengineered 13 (2022): 8323–8333.

[36] M. Wang, X. Han, Q. Wang, et al., “Checkpoint Kinase Wee1 Activation Drives Inflammation and Hypertrophy Through the Protein Kinase B/Phosphoinositide 3-Kinases-Nuclear Factor κB Pathway in Cardiomyocytes,” European Heart Journal 47 (2026): 1702–1717.

[37] B. Li, W.-W. Bai, T. Guo, et al., “Statins Improve Cardiac Endothelial Function to Prevent Heart Failure With Preserved Ejection Fraction Through Upregulating circRNA-RBCK1,” Nature Communications 15 (2024): 2953.

[38] S. Kawaguchi, B. Moukette, M. N. Sepúlveda, et al., “SPRR1A Is a Key Downstream Effector of MiR-150 During Both Maladaptive Cardiac Remodeling in Mice and Human Cardiac Fibroblast Activation,” Cell Death & Disease 14 (2023): 446.

[39] D. Yang, X. Wan, N. Schwieterman, et al., “MicroRNA-1 Deficiency Is a Primary Etiological Factor Disrupting Cardiac Contractility and Electrophysiological Homeostasis,” Circulation: Arrhythmia and Electrophysiology 17 (2024): e012150.

[40] Y. Luo, W. Gu, Z. Pan, et al., “MiR-1 Alleviates Chronic Heart Failure Through HCN2/HCN4 Axis In Vitro,” Tissue and Cell 95 (2025): 102921.

[41] T. Zhang, Y. Zhang, S. Li, et al., “Gentianella Acuta-Derived Gen-miR-1 Suppresses Myocardial Fibrosis by Targeting HAX1/HMG20A/Smads Axis to Attenuate Inflammation in Cardiac Fibroblasts,” Phytomedicine 118 (2023): 154923.

[42] X. Wu, L. Wang, K. Wang, et al., “ADAR2 Increases in Exercised Heart and Protects Against Myocardial Infarction and Doxorubicin-Induced Cardiotoxicity,” Molecular Therapy 30 (2022): 400–414.

[43] X. Shen, F. Zhi, C. Shi, et al., “The Involvement and Therapeutic Potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 Pathway in Arsenic Trioxide-Induced Cardiotoxicity,” Journal of Translational Medicine 21 (2023): 52.

[44] Y. Huang, Y. Huang, Z. Cai, et al., “MiR-21-3p Inhibitor Exerts Myocardial Protective Effects by Altering Macrophage Polarization State and Reducing Excessive Mitophagy,” Communications Biology 7 (2024): 1371.

[45] X. Li, C. Meng, F. Han, et al., “Vildagliptin Attenuates Myocardial Dysfunction and Restores Autophagy via miR-21/SPRY1/ERK in Diabetic Mice Heart,” Frontiers in Pharmacology 12 (2021): 634365.

[46] H. Li, X. Tian, Y. Ruan, et al., “Asiatic Acid Alleviates Ang-II Induced Cardiac Hypertrophy and Fibrosis via miR-126/PIK3R2 Signaling,” Nutrition & Metabolism 18 (2021): 71.

[47] X. Fan, G. Yang, Y. Wang, et al., “Exosomal Mir-126-3p Derived From Endothelial Cells Induces Ion Channel Dysfunction by Targeting RGS3 Signaling in Cardiomyocytes: A Novel Mechanism in Takotsubo Cardiomyopathy,” Stem Cell Research & Therapy 16 (2025): 36.

[48] M. Liu, D. Fu, T. Gao, et al., “The Low Expression of miR-155 Promotes the Expression of SHP2 by Inhibiting the Activation of the ERK1/2 Pathway and Improves Cell Pyroptosis Induced by I/R in Mice,” Aging (Albany NY) 16 (2024): 4778–4788.

[49] X. He, S. Liu, Z. Zhang, et al., “M1 Macrophage-Derived Exosomes Inhibit Cardiomyocyte Proliferation Through Delivering miR-155,” BMC Cardiovascular Disorders 24 (2024): 365.

[50] E. G. Rusu-Nastase, A.-M. Lupan, C. I. Marinescu, et al., “MiR-29a Increase in Aging May Function as a Compensatory Mechanism Against Cardiac Fibrosis Through SERPINH1 Downregulation,” Frontiers in Cardiovascular Medicine 8 (2021): 810241.

[51] X. Zhang, C. Liao, K. Sun, et al., “A Soluble Epoxide Hydrolase Inhibitor Upregulated KCNJ12 and KCNIP2 by Downregulating MicroRNA-29 in a Mouse Model of Myocardial Infarction,” Heart Surgery Forum 23 (2020): E579–E585.

[52] Y. Chen, S. Li, Y. Zhang, et al., “The lncRNA Malat1 Regulates Microvascular Function After Myocardial Infarction in Mice via miR-26b-5p/Mfn1 Axis-Mediated Mitochondrial Dynamics,” Redox Biology 41 (2021): 101910.

[53] S. Wang, T. Yao, F. Deng, et al., “LncRNA MALAT1 Promotes Oxygen-Glucose Deprivation and Reoxygenation Induced Cardiomyocytes Injury Through Sponging miR-20b to Enhance Beclin1-Mediated Autophagy,” Cardiovascular Drugs and Therapy 33 (2019): 675–686.

[54] S. Wang, J. Duan, J. Liao, et al., “LncRNA H19 Inhibits ER Stress-Induced Apoptosis and Improves Diabetic Cardiomyopathy by Regulating PI3K/AKT/mTOR Axis,” Aging (Albany NY) 14 (2022): 6809–6828.

[55] X. Yu, J. Huang, X. Liu, et al., “LncRNA H19 Acts as a ceRNA of Let-7G to Facilitate Endothelial-to-Mesenchymal Transition in Hypoxic Pulmonary Hypertension via Regulating TGF-β Signalling Pathway,” Respiratory Research 25 (2024): 270.

[56] J. Omura, K. Habbout, T. Shimauchi, et al., “Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension,” Circulation 142 (2020): 1464–1484.

[57] S. Mi, F. Huang, M. Jiao, et al., “Inhibition of MEG3 Ameliorates Cardiomyocyte Apoptosis and Autophagy by Regulating the Expression of miRNA-129-5p in a Mouse Model of Heart Failure,” Redox Report 28 (2023): 2224607.

[58] Y. Jiang, Y. Zhao, B.-Y. Jia, et al., “LncRNA MEG3 Independently Collaborates With lncRNA TUG1 to Prevent Cholesterol Efflux in Ox-LDL-Induced Human Umbilical Vein Endothelial Cells,” Molecular Biology Reports 52 (2025): 433.

[59] Y.-L. Xue, S.-X. Zhang, C.-F. Zheng, et al., “Long Non-Coding RNA MEG3 Inhibits M2 Macrophage Polarization by Activating TRAF6 via MicroRNA-223 Down-Regulation in Viral Myocarditis,” Journal of Cellular and Molecular Medicine 24 (2020): 12341–12354.

[60] Y. Dang, W. Hua, X. Zhang, et al., “Anti-Angiogenic Effect of Exo-LncRNA TUG1 in Myocardial Infarction and Modulation by Remote Ischemic Conditioning,” Basic Research in Cardiology 118 (2023): 1.

[61] Q. Duan, A. Dong, H. Cheng, et al., “Inhibition of Taurine-Upregulated Gene 1 Upregulates MiR-34a-5p to Protect Against Myocardial Ischemia/Reperfusion via Autophagy Regulation,” Combinatorial Chemistry & High Throughput Screening 28 (2025): 110–121.

[62] J. Xiong and Q. Zhou, “The lncRNA HOTAIR Attenuates Pyroptosis of Diabetic Cardiomyocytes by Recruiting FUS to Regulate SIRT3 Expression,” Kaohsiung Journal of Medical Sciences 39 (2023): 458–467.

[63] W. Tan, K. Wang, X. Yang, et al., “LncRNA HOTAIR Promotes Myocardial Fibrosis in Atrial Fibrillation Through Binding With PTBP1 to Increase the Stability of Wnt5a,” International Journal of Cardiology 369 (2022): 21–28.

[64] J. Chen, X. Li, F. Zhao, et al., “HOTAIR/miR-17-5p Axis Is Involved in the Propofol-Mediated Cardioprotection Against Ischemia/Reperfusion Injury,” Clinical Interventions in Aging 16 (2021): 621–632.

[65] S. Huang, L. Xue, and Q. Mou, “Emodin Regulates lncRNA XIST/miR-217 Axis to Protect Myocardial Ischemia-Reperfusion Injury,” Oxidative Medicine and Cellular Longevity 2023 (2023): 3612814.

[66] Q. Bai, Y. Li, K. Song, et al., “Knockdown of XIST Up-Regulates miR-340-5p to Relieve Myocardial Ischaemia-Reperfusion Injury via Inhibiting Cyclin D1,” ESC Heart Failure 9 (2022): 1050–1060.

[67] C. Chen, H. Shen, Q. Huang, et al., “The Circular RNA CDR1as Regulates the Proliferation and Apoptosis of Human Cardiomyocytes Through the miR-135a/HMOX1 and miR-135b/HMOX1 Axes,” Genetic Testing and Molecular Biomarkers 24 (2020): 537–548.

[68] H.-H. Geng, R. Li, Y.-M. Su, et al., “The Circular RNA Cdr1as Promotes Myocardial Infarction by Mediating the Regulation of miR-7a on Its Target Genes Expression,” PLoS ONE 11 (2016): e0151753.

[69] F. Ding, L. Lu, C. Wu, et al., “circHIPK3 Prevents Cardiac Senescence by Acting as a Scaffold to Recruit Ubiquitin Ligase to Degrade HuR,” Theranostics 12 (2022): 7550–7566.

[70] Y. Deng, J. Wang, G. Xie, et al., “Circ-HIPK3 Strengthens the Effects of Adrenaline in Heart Failure by miR-17-3p–ADCY6 Axis,” International Journal of Biological Sciences 15 (2019): 2484–2496.

[71] M. Fan, T. Liang, F. Xie, et al., “Exosomal circ_HIPK3 Reduces Apoptosis in H2O2-Induced AC16 Cardiomyocytes Through miR-33a-5p/IRS1 Axis,” Transplant Immunology 80 (2023): 101862.

[72] X. Si, H. Zheng, G. Wei, et al., “circRNA Hipk3 Induces Cardiac Regeneration After Myocardial Infarction in Mice by Binding to Notch1 and miR-133a,” Molecular Therapy—Nucleic Acids 21 (2020): 636–655.

[73] D. Zhu, S. Liu, K. Huang, et al., “Intrapericardial Exosome Therapy Dampens Cardiac Injury via Activating Foxo3,” Circulation Research 131 (2022): e135–e150.

[74] L. Kong, Y. Liu, J.-H. Wang, et al., “Linggui Zhugan Decoction Ameliorating Mitochondrial Damage of Doxorubicin-Induced Cardiotoxicity by Modulating the AMPK–FOXO3a Pathway Targeting BTG2,” Phytomedicine 139 (2025): 156529.

[75] B. Luo, Y. Wu, S.-L. Liu, et al., “Vagus Nerve Stimulation Optimized Cardiomyocyte Phenotype, Sarcomere Organization and Energy Metabolism in Infarcted Heart Through FoxO3A–VEGF Signaling,” Cell Death & Disease 11 (2020): 971.

[76] A. Bibi, A. Madè, S. Greco, et al., “Circular PVT1 Promotes Cardiac Fibroblast Activation Interacting With miR-30a-5p and miR-125b-5p,” Cell Death & Disease 16 (2025): 325.

[77] Q.-Q. Wu, Q. Yao, T.-T. Hu, et al., “Tax1 Banding Protein 1 Exacerbates Heart Failure in Mice by Activating ITCH–P73–BNIP3-Mediated Cardiomyocyte Apoptosis,” Acta Pharmacologica Sinica 43 (2022): 2562–2572.

[78] D. Han, Y. Wang, Y. Wang, et al., “The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a,” Circulation Research 127 (2020): e108–e125.

[79] S. R. Nayakanti, A. Friedrich, P. Sarode, et al., “Targeting Wnt-β-Catenin–FOSL Signaling Ameliorates Right Ventricular Remodeling,” Circulation Research 132 (2023): 1468–1485.

[80] Y. Bai, R. Li, J.-F. Hao, et al., “Accumulated β-Catenin Is Associated With Human Atrial Fibrosis and Atrial Fibrillation,” Journal of Translational Medicine 22 (2024): 734.

[81] H. Meng, Y. Deng, J. Liao, et al., “β-Catenin Mediates Monocrotaline-Induced Pulmonary Hypertension via Glycolysis in Rats,” BMC Cardiovascular Disorders 24 (2024): 381.

[82] Y. Sun, Y. Gu, H. Yao, et al., “The Role of miR-128 and MDFI in Cardiac Hypertrophy and Heart Failure: Mechanistic Insights,” Journal of Cellular and Molecular Medicine 28 (2024): e18546.

[83] G. Li, Y. Shao, H. C. Guo, et al., “MicroRNA-27b-3p Down-Regulates FGF1 and Aggravates Pathological Cardiac Remodelling,” Cardiovascular Research 118 (2022): 2139–2151.

[84] J. Wu, K. C. V. Subbaiah, F. Jiang, et al., “MicroRNA-574 Regulates FAM210A Expression and Influences Pathological Cardiac Remodeling,” EMBO Molecular Medicine 13 (2021): e12710.

[85] A. S. I. Ahmed, A. B. Blood, and L. Zhang, “MicroRNA-210 Mediates Hypoxia-Induced Pulmonary Hypertension by Targeting Mitochondrial Bioenergetics and mtROS Flux,” Acta Physiologica 240 (2024): e14212.

[86] Z. Düzgün, L. M. Kayıkçıoğlu, Ç. Aktan, et al., “Decreased Circulating MicroRNA-21 and MicroRNA-143 Are Associated With Pulmonary Hypertension,” Turkish Journal of Medical Sciences 53 (2023): 130–141.

[87] K. Goel, N. Egersdorf, A. Gill, et al., “Characterization of Pulmonary Vascular Remodeling and MicroRNA-126 Targets in COPD–Pulmonary Hypertension,” Respiratory Research 23 (2022): 349.

[88] K. Suzuki, H. Yamada, R. Fujii, et al., “Circulating MicroRNA-27a and -133a Are Negatively Associated With Incident Hypertension: A Five-Year Longitudinal Population-Based Study,” Biomarkers 27 (2022): 496–502.

[89] J. Wang, Y. Li, L. Deng, et al., “FTO Suppresses Cardiac Fibrosis After Myocardial Infarction via m6A-Mediated Epigenetic Modification of EPRS,” Molecular Medicine 30 (2024): 213.

[90] L. Li, H. Cheng, Y. Zhou, et al., “METTL3 Regulates Autophagy of Hypoxia-Induced Cardiomyocytes by Targeting ATG7,” Cell Death Discovery 11 (2025): 37.

[91] F. Zhang, L. Zhang, G. Hu, et al., “Rectifying METTL4-Mediated N6-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure,” Circulation 150 (2024): 1441–1458.

[92] Y. Liu, J. Deng, W. Ma, et al., “Ablation of lncRNA Miat Attenuates Pathological Hypertrophy and Heart Failure,” Theranostics 11 (2021): 7995–8007.

[93] H. Deng, W. Ouyang, L. Zhang, et al., “LncRNA GASL1 Is Downregulated in Chronic Heart Failure and Regulates Cardiomyocyte Apoptosis,” Cellular & Molecular Biology Letters 24 (2019): 41.

[94] Y. Ren and X. Zhao, “Bone Marrow Mesenchymal Stem Cells-Derived Exosomal lncRNA GAS5 Mitigates Heart Failure by Inhibiting UL3/Hippo Pathway-Mediated Ferroptosis,” European Journal of Medical Research 29 (2024): 303.

[95] X. Liu, H. Li, M. H. Hastings, et al., “miR-222 Inhibits Pathological Cardiac Hypertrophy and Heart Failure,” Cardiovascular Research 120 (2024): 262–272.

[96] P. Xue, Y. Liu, H. Wang, et al., “miRNA-103-3p–Hlf Regulates Apoptosis and Autophagy by Targeting Hepatic Leukaemia Factor in Heart Failure,” ESC Heart Failure 10 (2023): 3038–3045.

[97] Z. Huang, Z. Zeng, J. Li, et al., “High Expression of Circ-PALLD in Heart Failure Is Transcriptionally Regulated by the Transcription Factor GATA4,” Journal of Southern Medical University 43 (2023): 1371–1378.

[98] M. Bisserier, P. Mathiyalagan, S. Zhang, et al., “Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension,” Circulation 144 (2021): 52–73.

[99] X. Wang, Q. Li, S. He, et al., “LncRNA FENDRR With m6A RNA Methylation Regulates Hypoxia-Induced Pulmonary Artery Endothelial Cell Pyroptosis by Mediating DRP1 DNA Methylation,” Molecular Medicine 28 (2022): 126.

[100] X. Feng, K. Wang, T. Yang, et al., “LncRNA-GAS5/miR-382-3p Axis Inhibits Pulmonary Artery Remodeling and Promotes Autophagy in Chronic Thromboembolic Pulmonary Hypertension,” Genes & Genomics 44 (2022): 395–404.

[101] C. Liu, J. Chen, X. Huang, et al., “lncRNA VELRP Modulates Pulmonary Arterial Smooth Muscle Cell Proliferation and Promotes Vascular Remodeling in Pulmonary Hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology 44 (2024): 2560–2576.

[102] X. Liang, J. Zhou, H. Wang, et al., “miR-30d Attenuates Pulmonary Arterial Hypertension via Targeting MTDH and PDE5A and Modulates the Beneficial Effect of Sildenafil,” Advanced Science 11 (2024): e2407712.

[103] S. He, J. Bai, L. Zhang, et al., “Superenhancer-Driven circRNA Myst4 Is Involved in Pulmonary Artery Smooth Muscle Cell Ferroptosis in Pulmonary Hypertension,” Iscience 27 (2024): 110900.

[104] C. Ma, R. Gu, X. Wang, et al., “circRNA CDR1as Promotes Pulmonary Artery Smooth Muscle Cell Calcification by Upregulating CAMK2D and CNN3 via Sponging miR-7-5p,” Molecular Therapy: Nucleic Acids 22 (2020): 530–541.

[105] X. Jing, S. Wu, Y. Liu, et al., “Circular RNA Sirtuin1 Represses Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Autophagy to Ameliorate Pulmonary Hypertension via Targeting microRNA-145-5p/Protein Kinase B3 Axis,” Bioengineered 13 (2022): 8759–8771.

[106] W. Liu, G. Tan, X. Li, et al., “LncRNA TONSL-AS1 Participates in Coronary Artery Disease by Interacting With miR-197,” Microvascular Research 136 (2021): 104152.

[107] T. Xiong, B. Xiao, Y. Wu, et al., “Upregulation of the Long Non-Coding RNA LINC01480 Is Associated With Immune Infiltration in Coronary Artery Disease Based on an Immune-Related lncRNA-mRNA Co-Expression Network,” Frontiers in Cardiovascular Medicine 9 (2022): 724262.

[108] Y. Zhang, Y. Wang, L. Zhang, et al., “Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis,” Circulation Research 127 (2020): 855–873.

[109] A. Gholipour, A. Zahedmehr, M. Arabian, et al., “MiR-6721-5p as a Natural Regulator of Meta-VCL Is Upregulated in the Serum of Patients With Coronary Artery Disease,” Noncoding RNA Research 10 (2025): 25–34.

[110] Z. Pan, J. Lv, L. Zhao, et al., “CircARCN1 Aggravates Atherosclerosis by Regulating HuR-Mediated USP31 mRNA in Macrophages,” Cardiovascular Research 120 (2024): 1531–1549.

[111] Y. Fu, Q. Jia, M. Ren, et al., “Circular RNA ZBTB46 Depletion Alleviates the Progression of Atherosclerosis by Regulating the Ubiquitination and Degradation of hnRNPA2B1 via the AKT/mTOR Pathway,” Immunity & Ageing 20 (2023): 66.

[112] J. Zhang, Y. Tang, J. Zhang, et al., “CircRNA ACAP2 Is Overexpressed in Myocardial Infarction and Promotes the Maturation of miR-532 to Induce the Apoptosis of Cardiomyocytes,” Journal of Cardiovascular Pharmacology 78 (2021): 247–252.

[113] L. Yan, N. Guo, Y. Cao, et al., “miRNA-145 Inhibits Myocardial Infarction-Induced Apoptosis Through Autophagy via Akt3/mTOR Signaling Pathway In Vitro and In Vivo,” International Journal of Molecular Medicine 42 (2018): 1537–1547.

[114] H.-F. Zheng, J. Sun, Z.-Y. Zou, et al., “MiRNA-488-3p Suppresses Acute Myocardial Infarction-Induced Cardiomyocyte Apoptosis via Targeting ZNF791,” European Review for Medical and Pharmacological Sciences 23 (2019): 4932–4939.

[115] Y.-W. Wang, H.-Z. Dong, Y.-X. Tan, et al., “HIF-1α-Regulated lncRNA-TUG1 Promotes Mitochondrial Dysfunction and Pyroptosis by Directly Binding to FUS in Myocardial Infarction,” Cell Death Discovery 8 (2022): 178.

[116] S. Bai, X. Wang, Y. Hou, et al., “lncRNA-056298 Regulates GAP43 and Promotes Cardiac Intrinsic Autonomic Nerve Remodelling in a Canine Model of Atrial Fibrillation Induction After Ganglionated Plexus Ablation,” Current Medicinal Chemistry 32 (2025): 136–159.

[117] W. W. Du, M. Rafiq, H. Yuan, et al., “A Novel Protein NAB1-356 Encoded by circRNA circNAB1 Mitigates Atrial Fibrillation by Reducing Inflammation and Fibrosis,” Advanced Science 12 (2025): e2411959.

[118] Z. Wei, Y. Lu, C. Qian, et al., “Circ_0079480 Facilitates Proliferation, Migration and Fibrosis of Atrial Fibroblasts in Atrial Fibrillation by Sponging miR-338-3p to Activate the THBS1/TGF-β1/Smad3 Signaling,” International Journal of Cardiology 416 (2024): 132486.

[119] H. Wang, W. Jiang, Y. Hu, et al., “Quercetin Improves Atrial Fibrillation Through Inhibiting the TGF-β/Smads Pathway via Promoting miR-135b Expression,” Phytomedicine 93 (2021): 153774.

[120] X. Fan, K. Feng, Y. Liu, et al., “miR-135a Regulates Atrial Fibrillation by Targeting Smad3,” Cardiovascular Therapeutics 2023 (2023): 8811996.

[121] Z. Qi, R. Liu, H. Ju, et al., “microRNA-130b-3p Attenuates Septic Cardiomyopathy by Regulating the AMPK/mTOR Signaling Pathways and Directly Targeting ACSL4 Against Ferroptosis,” International Journal of Biological Sciences 19 (2023): 4223–4241.

[122] B. Liu, Y. Wei, J. He, et al., “Human Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Myocardial Fibrosis and Restore miRNA-133a Expression in Diabetic Cardiomyopathy,” Stem Cell Research & Therapy 15 (2024): 120.

[123] H. Du, Y. Zhao, J. Wen, et al., “LncRNA DCRT Protects Against Dilated Cardiomyopathy by Preventing NDUFS2 Alternative Splicing by Binding to PTBP1,” Circulation 150 (2024): 1030–1049.

[124] X. Nie, J. Fan, B. Dai, et al., “LncRNA CHKB-DT Downregulation Enhances Dilated Cardiomyopathy Through ALDH2,” Circulation Research 134 (2024): 425–441.

[125] W. Wang, S. Zhang, L. Xu, et al., “Involvement of circHIPK3 in the Pathogenesis of Diabetic Cardiomyopathy in Mice,” Diabetologia 64 (2021): 681–692.

[126] J. Jiang, G. Gao, Q. Pan, et al., “Circular RNA circHIPK3 Is Downregulated in Diabetic Cardiomyopathy and Overexpression of circHIPK3 Suppresses PTEN to Protect Cardiomyocytes From High Glucose-Induced Cell Apoptosis,” Bioengineered 13 (2022): 6272–6279.

[127] A. Bonanni, M. Basile, R. A. Montone, et al., “Impact of the Exposome on Cardiovascular Disease,” European Heart Journal Supplements 25, no. suppl B (2023): B60–B64.

[128] J. Domínguez-Barragán, A. Fernández-Sanlés, Á. Hernáez, et al., “Blood DNA Methylation Signature of Diet Quality and Association With Cardiometabolic Traits,” European Journal of Preventive Cardiology 31 (2024): 191–202.

[129] S. Yuan, Q. Ye, and R. Qin, “Cardioepigenetics in Action: Aerobic Exercise-Induced Modulation of miRNAs, lncRNAs, and Chromatin Remodeling in Cardiovascular Disease,” Frontiers in Cardiovascular Medicine 12 (2025): 1579352.

[130] L. A. Opsasnick, W. Zhao, S. M. Ratliff, et al., “Epigenome-Wide Mediation Analysis of the Relationship Between Psychosocial Stress and Cardiometabolic Risk Factors in the Health and Retirement Study (HRS),” Clinical Epigenetics 16 (2024): 180.

[131] A. T. Lu, A. M. Binder, J. Zhang, et al., “DNA Methylation GrimAge Version 2,” Aging (Albany NY) 14 (2022): 9484–9549.

[132] A. L. Koenig, I. Shchukina, J. Amrute, et al., “Single-Cell Transcriptomics Reveals Cell-Type-Specific Diversification in Human Heart Failure,” Nature Cardiovascular Research 1 (2022): 263–280.

[133] R. R. C. Cuadrat, A. Kratzer, and H. Giral Arnal, “Cardiovascular Disease Biomarkers Derived From Circulating Cell-Free DNA Methylation,” NAR Genomics and Bioinformatics 5 (2023): lqad061.

[134] Y. Jiang and T. Du, “Relation of Circulating lncRNA GAS5 and miR-21 With Biochemical Indexes, Stenosis Severity, and Inflammatory Cytokines in Coronary Heart Disease Patients,” Journal of Clinical Laboratory Analysis 36 (2022): e24202.

[135] Q. Yin, A. Wu, and M. Liu, “Plasma Long Non-Coding RNA (lncRNA) GAS5 Is a New Biomarker for Coronary Artery Disease,” Medical Science Monitor 23 (2017): 6042–6048.

[136] J. Zhou, X. Duan, J. Wang, et al., “Valsartan Regulates PI3K/AKT Pathways Through lncRNA GASL1 to Improve Isoproterenol-Induced Heart Failure,” Disease Markers 2022 (2022): 1447399.

[137] Q. Yu, N. Zhang, X. Gan, et al., “EGCG Attenuated Acute Myocardial Infarction by Inhibiting Ferroptosis via miR-450b-5p/ACSL4 Axis,” Phytomedicine 119 (2023): 154999.

[138] P. F. Koch, M. C. García-Hidalgo, J. Labus, et al., “Circulating Long Noncoding RNA PDE4DIPP6: A Novel Biomarker for Improving the Clinical Management of Non-ST-Segment Elevation Myocardial Infarction,” Clinica Chimica Acta 561 (2024): 119840.

[139] S.-M. Wang, G.-Q. Liu, H.-B. Xian, et al., “LncRNA NEAT1 Alleviates Sepsis-Induced Myocardial Injury by Regulating the TLR2/NF-κB Signaling Pathway,” European Review for Medical and Pharmacological Sciences 23 (2019): 4898–4907.

[140] L. Zhu, X. Lin, and M. Chen, “LncRNA NEAT1 Correlates With Th17 Cells and Proinflammatory Cytokines, Also Reflects Stenosis Degree and Cholesterol Level in Coronary Heart Disease Patients,” Journal of Clinical Laboratory Analysis 36 (2022): e23975.

[141] C.-L. Cai, L. Jin, X.-L. Lang, et al., “Long Noncoding RNA XIST Regulates Cardiomyocyte Apoptosis by Targeting miR-873-5p/MCL1 Axis,” European Review for Medical and Pharmacological Sciences 24 (2020): 12878–12886.

[142] X. Liu, Z. Tong, K. Chen, et al., “The Role of miRNA-132 Against Apoptosis and Oxidative Stress in Heart Failure,” BioMed Research International 2018 (2018): 3452748.

[143] J. Täubel, W. Hauke, S. Rump, et al., “Novel Antisense Therapy Targeting microRNA-132 in Patients With Heart Failure: Results of a First-in-Human Phase 1b Randomized, Double-Blind, Placebo-Controlled Study,” European Heart Journal 42 (2021): 178–188.

[144] X. Liu, M. Wang, Q. Li, et al., “CircRNA ACAP2 Induces Myocardial Apoptosis After Myocardial Infarction by Sponging miR-29,” Minerva Medica 113 (2022): 128–134.

[145] X. Liu, Y. Xu, Y. Deng, et al., “MicroRNA-223 Regulates Cardiac Fibrosis After Myocardial Infarction by Targeting RASA1,” Cellular Physiology and Biochemistry 46 (2018): 1439–1454.

[146] C. Schulte, S. Molz, S. Appelbaum, et al., “miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients With Symptomatic Coronary Artery Disease,” PLoS ONE 10 (2015): e0145930.

[147] Q. Zhu, S. Li, K. Ji, et al., “Differentially Expressed TUG1 and miR-145-5p Indicate Different Severity of Chronic Heart Failure and Predict 2-Year Survival Prognosis,” Experimental and Therapeutic Medicine 22 (2021): 1362.

[148] B. Li and Y. Wu, “LncRNA TUG1 Overexpression Promotes Apoptosis of Cardiomyocytes and Predicts Poor Prognosis of Myocardial Infarction,” Journal of Clinical Pharmacy and Therapeutics 45 (2020): 1452–1456.

[149] J. S. Y. Ho, E. Jou, P.-L. Khong, et al., “Epigenetics in Heart Failure,” International Journal of Molecular Sciences 25 (2024): 12010.

[150] Y. Qiu, Q. Xu, P. Xie, et al., “Epigenetic Modifications and Emerging Therapeutic Targets in Cardiovascular Aging and Diseases,” Pharmacological Research 211 (2025): 107546.

[151] F. Shang, X. Guo, Y. Chen, et al., “Endothelial MicroRNA-483-3p Is Hypertension-Protective,” Oxidative Medicine and Cellular Longevity 2022 (2022): 3698219.

[152] M. Ala, I. M. Khawajah, and S. S. Khamene, “BET Inhibitors in Cardiovascular Diseases: From Atherosclerosis to Heart Failure,” Pharmacological Reports 78 (2026): 405–422.

[153] S. J. Nicholls, G. G. Schwartz, K. A. Buhr, et al., “Apabetalone and Hospitalization for Heart Failure in Patients Following an Acute Coronary Syndrome: A Prespecified Analysis of the BETonMACE Study,” Cardiovascular Diabetology 20 (2021): 13.

[154] Y. Shi, H. Zhang, S. Huang, et al., “Epigenetic Regulation in Cardiovascular Disease: Mechanisms and Advances in Clinical Trials,” Signal Transduction and Targeted Therapy 7 (2022): 200.

[155] Y. Ren, B. Zhao, L. Lv, et al., “Non-Coding RNAs in Heart Failure: Epigenetic Regulatory Mechanisms and Therapeutic Potential,” Frontiers in Genetics 16 (2025): 1677797.

[156] K. Xie, J. Zeng, L. Wen, et al., “Abnormally Elevated EZH2-Mediated H3K27me3 Enhances Osteogenesis in Aortic Valve Interstitial Cells by Inhibiting SOCS3 Expression,” Atherosclerosis 364 (2023): 1–9.

[157] S.-I. Inoue, S. Takahara, T. Yoshikawa, et al., “Activated Braf Induces Esophageal Dilation and Gastric Epithelial Hyperplasia in Mice,” Human Molecular Genetics 26 (2017): 4715–4727.

[158] S.-I. Inoue, M. Moriya, Y. Watanabe, et al., “New BRAF Knockin Mice Provide a Pathogenetic Mechanism of Developmental Defects and a Therapeutic Approach in Cardio-Facio-Cutaneous Syndrome,” Human Molecular Genetics 23 (2014): 6553–6566.

[159] H. Zhong, R. Zhang, G. Li, et al., “c-JUN Is a Barrier in hESC to Cardiomyocyte Transition,” Life Science Alliance 6 (2023): e202302121.

[160] L. He, Y. Wang, and J. Luo, “Epigenetic Modification Mechanism of Histone Demethylase KDM1A in Regulating Cardiomyocyte Apoptosis After Myocardial Ischemia-Reperfusion Injury,” PeerJ 10 (2022): e13823.

[161] P. Cheng, H. Han, F. Chen, et al., “Amelioration of Acute Myocardial Infarction Injury Through Targeted Ferritin Nanocages Loaded With an ALKBH5 Inhibitor,” Acta Biomaterialia 140 (2022): 481–491.

[162] T. C. Karagiannis, M. Wall, K. Ververis, et al., “Characterization of K562 Cells: Uncovering Novel Chromosomes, Assessing Transferrin Receptor Expression, and Probing Pharmacological Therapies,” Cellular and Molecular Life Sciences 80 (2023): 248.

[163] C.-N. Chen, N. Hajji, F.-C. Yeh, et al., “Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology,” American Journal of Respiratory and Critical Care Medicine 208 (2023): 879–895.

[164] M. Abdellatif, V. Trummer-Herbst, F. Koser, et al., “Nicotinamide for the Treatment of Heart Failure With Preserved Ejection Fraction,” Science Translational Medicine 13 (2021): eabd7064.

[165] Y.-C. Wang, Y. C. Koay, C. Pan, et al., “Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction,” Circulation Research 134 (2024): 371–389.

[166] K. Liu, Y. Zhu, W. Gao, et al., “Resveratrol Alleviates Heart Failure by Activating Foxo3a to Counteract Oxidative Stress and Apoptosis,” Biomedicine & Pharmacotherapy 181 (2024): 117716.

[167] L. Zhang, J. Chen, L. Yan, et al., “Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction,” Frontiers in Pharmacology 12 (2021): 646240.

[168] Y. Li, J. Yu, C. Cheng, et al., “Platelet and Erythrocyte Membranes Coassembled Biomimetic Nanoparticles for Heart Failure Treatment,” ACS Nano 18 (2024): 26614–26630.

[169] M. S. Stratton, R. A. Bagchi, M. B. Felisbino, et al., “Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation,” Circulation Research 125 (2019): 662–677.

[170] S. R. Boovarahan and G. A. Kurian, “Preconditioning the Rat Heart With 5-Azacytidine Attenuates Myocardial Ischemia/Reperfusion Injury via PI3K/GSK3β and Mitochondrial KATP Signaling Axis,” Journal of Biochemical and Molecular Toxicology 35 (2021): e22911.

[171] H. H. Cho, S. Rhee, D. I. Cho, et al., “IKKε-Deficient Macrophages Impede Cardiac Repair After Myocardial Infarction by Enhancing the Macrophage-Myofibroblast Transition,” Experimental & Molecular Medicine 56 (2024): 2052–2064.

[172] J. Stenzig, Y. Schneeberger, A. Löser, et al., “Pharmacological Inhibition of DNA Methylation Attenuates Pressure Overload-Induced Cardiac Hypertrophy in Rats,” Journal of Molecular and Cellular Cardiology 120 (2018): 53–63.

[173] J. Stenzig, M. N. Hirt, A. Löser, et al., “DNA Methylation in an Engineered Heart Tissue Model of Cardiac Hypertrophy: Common Signatures and Effects of DNA Methylation Inhibitors,” Basic Research in Cardiology 111 (2016): 9.

[174] H. Lau, P. G. Woost, U. Friedrich, et al., “Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Decitabine and Tetrahydrouridine,” European Journal of Haematology 111 (2023): 345–355.

[175] M. Goswami, G. Gui, L. W. Dillon, et al., “Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,” Journal for ImmunoTherapy of Cancer 10 (2022): e003392.

[176] S. Toldo, A. Das, E. Mezzaroma, et al., “Induction of microRNA-21 With Exogenous Hydrogen Sulfide Attenuates Myocardial Ischemic and Inflammatory Injury in Mice,” Circulation: Cardiovascular Genetics 7 (2014): 311–320.

[177] Z. Huang, X.-J. Chen, C. Qian, et al., “Signal Transducer and Activator of Transcription 3/MicroRNA-21 Feedback Loop Contributes to Atrial Fibrillation by Promoting Atrial Fibrosis in a Rat Sterile Pericarditis Model,” Circulation: Arrhythmia and Electrophysiology 9 (2016): e003396.

[178] Z. Wu, X. Chen, J. Ye, et al., “Pericarpium Trichosanthis Injection Protects Isoproterenol-Induced Acute Myocardial Ischemia via Suppressing Inflammatory Damage and Apoptosis Pathways,” Biomolecules 15 (2025): 618.

[179] K. Liu, L. Zheng, Q.-Y. Huang, et al., “Natural Product Library Screening Identifies Darutigenol for the Treatment of Myocardial Infarction and Ischemia/Reperfusion Injury,” Chinese Medicine 20 (2025): 90.

[180] A. Nebbioso, C. Dell'Aversana, A. Bugge, et al., “HDACs Class II-Selective Inhibition Alters Nuclear Receptor-Dependent Differentiation,” Journal of Molecular Endocrinology 45 (2010): 219–228.

[181] B. Lkhagva, S.-L. Chang, Y.-C. Chen, et al., “Histone Deacetylase Inhibition Reduces Pulmonary Vein Arrhythmogenesis Through Calcium Regulation,” International Journal of Cardiology 177 (2014): 982–989.

[182] X. Xu, M. Elkenani, X. Tan, et al., “DNA Methylation Analysis Identifies Novel Epigenetic Loci in Dilated Murine Heart Upon Exposure to Volume Overload,” International Journal of Molecular Sciences 24 (2023): 5885.

[183] N. Glezeva, B. Moran, P. Collier, et al., “Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes,” Circulation: Heart Failure 12 (2019): e005765.

[184] Resverlogix Corp., “Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD (BETonMACE),” ClinicalTrials.gov Identifier: NCT02586155 (2015).

[185] Phase II Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial for Dose-Finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease [Z]. 2010.

[186] M. S. Willis, J. W. Homeister, G. B. Rosson, et al., “Functional Redundancy of SWI/SNF Catalytic Subunits in Maintaining Vascular Endothelial Cells in the Adult Heart,” Circulation Research 111 (2012): e111–e122.

[187] M. Rosa-Garrido, D. J. Chapski, A. D. Schmitt, et al., “High-Resolution Mapping of Chromatin Conformation in Cardiac Myocytes Reveals Structural Remodeling of the Epigenome in Heart Failure,” Circulation 136 (2017): 1613–1625.

[188] G. C. Kuşçu, E. Tut, Ç. Gürel, et al., “Mitochondrial Dynamics-Related Gene Regulation by Epigenetic Suppression of GCN5 Exerts Neuroprotective Effects in Rotenone-Induced Parkinson's Disease Model,” Molecular Neurobiology 63 (2026): 383.

[189] L. Xiao, Z. Zhang, T. Li, et al., “Small Extracellular Vesicles From Human Amniotic Membrane Mesenchymal Stem Cells Rejuvenate Senescent β Cells and Cure Age-Related Diabetes in Mice,” Aging Cell 25 (2026): e70327.

[190] Y. Wang, X. Yu, F. Sun, et al., “METTL14 Mediates Glut3 m6A Methylation to Improve Osteogenesis Under Oxidative Stress Condition,” Redox Report 30 (2025): 2435241.

[191] X. Wang, C. Zou, M. Li, et al., “METTL14 Upregulates TCF1 Through m6A mRNA Methylation to Stimulate Osteogenic Activity in Osteoporosis,” Human Cell 36 (2023): 178–194.

[192] A. Russell-Hallinan, R. Neary, C. J. Watson, et al., “Repurposing From Oncology to Cardiology: Low-Dose 5-Azacytidine Attenuates Pathological Cardiac Remodeling in Response to Pressure Overload Injury,” Journal of Cardiovascular Pharmacology and Therapeutics 26 (2021): 375–385.

[193] A. Spahillari, L. Jackson, D. Varrias, et al., “MicroRNAs Are Associated With Cardiac Biomarkers, Cardiac Structure and Function and Incident Outcomes in Heart Failure,” ESC Heart Failure 11 (2024): 1400–1410.

[194] X. Fang, R. Song, J. Wei, et al., “Mining Potential Drug Targets and Constructing Diagnostic Models for Heart Failure Based on miRNA-mRNA Networks,” Mediators of Inflammation 2022 (2022): 9652169.

[195] H. Yang, L. Shan, Y. Gao, et al., “MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure,” Disease Markers 2021 (2021): 4572282.

[196] W. Li, Y. Li, F. Jiang, et al., “Correlation Between Serum Levels of MicroRNA-21 and Inflammatory Factors in Patients With Chronic Heart Failure,” Medicine 101 (2022): e30596.

[197] X. Shao, X. Zhang, L. Yang, et al., “Integrated Analysis of mRNA and MicroRNA Expression Profiles Reveals Differential Transcriptome Signature in Ischaemic and Dilated Cardiomyopathy Induced Heart Failure,” Epigenetics 16 (2021): 917–932.

[198] B. G. McKenna, A. A. Lussier, M. J. Suderman, et al., “Strengthening Rigor and Reproducibility in Epigenome-Wide Association Studies of Social Exposures and Brain-Based Health Outcomes,” Current Environmental Health Reports 12 (2025): 19.

[199] G. B. A. Wisman, T. K. Wojdacz, L. Altucci, et al., “Clinical Promise and Applications of Epigenetic Biomarkers,” Clinical Epigenetics 16 (2024): 192.

[200] A. A. Lussier, Y. Zhu, B. J. Smith, et al., “Updates to Data Versions and Analytic Methods Influence the Reproducibility of Results From Epigenome-Wide Association Studies,” Epigenetics 17 (2022): 1373–1388.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.